A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...

Decision expected on new Alzheimer’s treatment - The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

New research shows astrocytes can remove Alzheimer’s-related amyloid-beta via autophagy, offering a promising new direction ...

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

Posterial Cortical Atrophy, sometimes called Benson’s disease, is a rare degenerative brain condition that affects the back ...

An analysis of the genetic activity of brain cells in individuals who have died with Alzheimer's disease has revealed the ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...